The EUROPEAN ASSOCIATION of NeuroOncology

MARSEILLE PARC CHANOT Convention & Exhibition Centre FRANCE

10th MEETING September 6-9 2012

MARSEILLE

PARC CHANOT Convention & Exhibition Centre FRANCE

FINAL PROGRAMME www.eano.eu
In the world of oncology

Combination is key

Merck Serono Oncology combines approaches that target

Tumor cell
Tumor environment
Immune system

to optimize therapeutic success
# Table of Contents

## General
- Committees, Boards, Organisation .............................................................. 2
- Welcoming Address .......................................................................................... 3
- Overview Marseille & Map .............................................................................. 4
- Acknowledgements – EANO 2014 – CME Credits ............................................ 5
- Floorplan of the Palais des congrès ................................................................. 6
- Programme at a Glance .................................................................................... 7

## Scientific Programme
- Thursday, September 6, 2012 (Educational Day) ........................................... 8
- Friday, September 7, 2012 (Nurses Session) .................................................. 10
- Saturday, September 8, 2012 ......................................................................... 15
- Sunday, September 9, 2012 ........................................................................... 19
- Side Meetings .................................................................................................. 20
- Corporate Satellite Meetings .......................................................................... 21
- Scientific Information ....................................................................................... 22
- Poster Topics ................................................................................................... 24

## General Information
- Social Events ................................................................................................... 25
- General Information ......................................................................................... 26
- Registration Fees ............................................................................................. 30

## Exhibition
- Exhibitors Standing ......................................................................................... 32
- Exhibitors Listing ............................................................................................. 33

Printed in Austria by: ROBIDRUCK, 1200 Vienna – www.robidruck.co.at
**COMMITTEES – BOARD – ORGANISATION**

### EANO X Organising Committee

Olivier Chinot (President, Marseille)  
Marylin Barrié (Marseille)  
Celine Bequet (Marseille)  
Henri Dufour (Marseille)  
Dominique Figarella-Branger (Marseille)  
Nadine Girard (Marseille)  
Philippe Metellus (Marseille)  
L’Houcine Ouafik (Marseille)  
Laetitia Padovani (Marseille)  
Jean Regis (Marseille)

---

### EANO Board

Wolfgang Grisold, President (AT)  
Robin Grant, Past President (UK)  
Clemens Dirven, Treasurer (NL)  
Ufuk Abacioglu, Board Member (TR)  
Lorenzo Bello, Board Member (IT)  
Beatrice Melin, Board Member (SE)  
Riccardo Soffietti, Board Member (IT)  
Michael Weller, Board Member (CH)  
Wolfgang Wick, Board Member (DE)  
Khe Hoang Xuan, Board Member (FR)  
Hanneke Zwinkels, Nurse Member (NL)

---

### EANO Secretariat

Mrs. Philomène Klomp  
P.O. Box 219  
5170 AE Kaatsheuvel  
The Netherlands  
T: +31 416 54 00 37  
F: +31 848398070  
office@eano.eu  
www.eano.eu

---

### Exhibition and Advertisements

Medizinische Ausstellungs- und Werbegesellschaft (MAW)  
Mrs. Andrea Etz, Mrs. Simone Biach  
Freyung 6  
1010 Vienna, Austria  
T: +43 1 536 63 - 42  
F: +43 1 535 60 16  
maw@media.co.at

---

### Conference Organisation, Abstract Management, Sponsoring

EANO 2012 Secretariat  
Vienna Medical Academy (VMA)  
Mrs. Romana Koenig  
Mrs. Alissa McGregor  
Alser Strasse 4, 1090 Vienna, Austria  
T: +43 1 405 13 83 0  
F: +43 1 407 82 74  
eano2012@medacad.org  
www.medacad.org

---

### Hotel Accommodation

Mondial & Cititravel Congresos  
Rosselló, 303, àtic 1  
08037 Barcelona – Spain  
T: +34 932 212 955  
F: + 34 934 492 059  
eano2012@mondial-congress.com  
www.mondial-congress.com

---

### Tours and Social Programme

Voyages C.Mathez  
Mrs. Laurence Berthelier  
33 cours Pierre Puget  
13006 Marseille, France  
T : +33 (0) 4 96 10 24 80  
F: + 33 (0) 4 96 10 24 82  
laurence.berthelier@matheztravel.com  
www.matheztravel.com
Dear colleagues and friends,

The French Society "Association des Neuro-Oncologues d’Expression Française ANOCEF" is very pleased and honored to welcome the 10th EANO 2012 conference in Marseille, and invites you to join this outstanding event for neuro-oncology in Europe and worldwide.

Increasing interest for neuro-oncology has been observed in recent years, related in part to increased knowledge of brain tumors and progress in diagnosis and therapies of these diseases. As a consequence, the EANO meeting exerts an increasing role by stimulating and giving access to research and knowledge in the different aspects of neuro-oncology. This educational and scientific event will give the opportunity to share and discuss the most up-to-date works in basic science, translational and clinical research, with an extended multidisciplinary approach that will cover among others biology, imaging, surgery, radiotherapy, chemotherapy and experimental therapies. The Scientific committee has developed an attractive programme that reflects present and future challenges in neuro-oncology that we hope you will truly enjoyable.

Marseille, European City of Culture in 2013, combines tradition and modernity with 26 centuries of history with Greek and Roman origins. Marseille constitutes an attractive place located in the South of France, opening to Provence history, landscapes and lifestyle and to the Mediterranean coast. Marseille has developed modern conference facilities with expanding success, reinforced by cultural and architectural landmarks and easy access to unforgettable sites such as Camargue, Luberon, Aix-en-Provence and the natural surroundings of Calanques forming hidden coves on the coast. ANOCEF will join its forces to the local organizing committee to do its very best to make your stay in Marseille fruitful, pleasant and memorable.

We look forward to welcoming you in Marseille.

Olivier Chinot
President, Organizing Committee
EANO 2012, President of ANOCEF

Wolfgang Grisold
President, EANO

Khe Hoang-Xuan
Scientific Secretary, Organising Committee EANO 2012

Congress Venue EANO X
PARC CHANOT, Marseille Exhibition & Convention centre
SAFIM - Parc Chanot
Rond Point du Prado
13008 MARSEILLE

Tel: +33 491761600
www.parc-chanot.com
The European Association of NeuroOncology gratefully acknowledges the support of the following companies and organisations (as per date of printing):

**Platinum Sponsor:**

![MSD](image)

![MERCK](image)

![MerckSerono](image)

![Roche](image)

**Future EANO Conference**

11th Meeting of the European Association of NeuroOncology
October, 9-12, 2014
Turin, Italy

**CME Credits**

The 10th Meeting of the European Association of NeuroOncology (EANO 2012) was granted **21** European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). The EACCME is an Institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The rules of the EACCME state that participants are kindly asked to fill in the feedback (evaluation) form included in the conference bag. It can be returned to the registration desk.
## Thursday, September 6, 2012 Educational Day (Registration will start at 08.00)

<table>
<thead>
<tr>
<th>Time</th>
<th>Callelongue</th>
<th>Riou</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00–09.30</td>
<td>Access to tumor tissue</td>
<td></td>
</tr>
<tr>
<td>09.30–10.00</td>
<td>Screening for a target</td>
<td></td>
</tr>
<tr>
<td>10.00–10.30</td>
<td>Testing a target Preclinical</td>
<td></td>
</tr>
<tr>
<td>10.30–11.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11.00–11.30</td>
<td>First clinical steps of a drug</td>
<td></td>
</tr>
<tr>
<td>11.30–12.30</td>
<td>Translational studies in phases I-II</td>
<td></td>
</tr>
<tr>
<td>12.30–13.30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13.00–14.30</td>
<td>Optimizing phases II and III for the future</td>
<td></td>
</tr>
<tr>
<td>14.00–15.30</td>
<td>End point in Phases III</td>
<td></td>
</tr>
<tr>
<td>15.00–16.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16.00–17.00</td>
<td>Quality of life issues</td>
<td></td>
</tr>
<tr>
<td>17.00–17.30</td>
<td>Late toxicities in patients with brain tumor</td>
<td></td>
</tr>
<tr>
<td>17.45–18.45</td>
<td>Satellite Symposium Merck Serono</td>
<td></td>
</tr>
</tbody>
</table>

### 20.00 Networking Event at Fort Ganteaume

## Friday, September 7, 2012

### 09.00–17.00 Room Riou: Nursing Research and Care Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Callelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00–09.00</td>
<td>Meet The Experts Session: A. Metastases</td>
<td>Meet The Experts Session: B. Symptom management and palliative care</td>
<td>Meet The Experts Session: C. New imaging techniques</td>
</tr>
<tr>
<td>09.10–10.35</td>
<td>Cell Biology and Signalling I</td>
<td>Epidemiology &amp; Neurotoxicity</td>
<td>Quality of Life &amp; Supportive Care</td>
</tr>
<tr>
<td>10.35–11.00</td>
<td>Coffee break</td>
<td>Coffee break</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.00–13.00</td>
<td>Immunotherapy and Biomarkers</td>
<td>11.00–13.10 Non-glial Tumors and Imaging</td>
<td>Presented Poster Discussion</td>
</tr>
<tr>
<td>13.00–14.00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00–14.15</td>
<td>Presidential address: Wolfgang Grisold</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15–15.45</td>
<td>Plenary session: Brain Tumor Microenvironment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.45–17.00</td>
<td>Poster Viewing and Coffee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00–18.00</td>
<td>Keynote lecture: Epidemiology/Risk Factors</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 18.00–19.30 Satellite Symposium MSD

## Saturday, September 8, 2012

### 08.00–09.00

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Callelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.10–10.00</td>
<td>Late breaking abstracts</td>
<td>Meet The Experts Session: B. The biology behind molecular markers?</td>
<td>Meet The Experts Session: C. Pediatric brain tumors</td>
</tr>
<tr>
<td>10.00–10.30</td>
<td>Coffee break</td>
<td>Coffee break</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30–12.30</td>
<td>Gloma-clinical studies and Neuroimaging</td>
<td>Gloma-experimental &amp; biomarkers</td>
<td>Presented Poster Discussion: Paraneoplastic Syndromes, PCNSL and other non-glial tumors</td>
</tr>
<tr>
<td>12.30–13.30</td>
<td>Lunch</td>
<td>Lunch</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.30–15.00</td>
<td>Plenary Session: Optimizing local non-surgical treatment in gloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00–15.45</td>
<td>Poster Viewing and Coffee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.45–16.15</td>
<td>Keynote Lecture: Epigenetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45–17.15</td>
<td>Poster Viewing and Coffee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.15–18.45</td>
<td>Satellite Symposium Prime Oncology</td>
<td>EANO General Assembly</td>
<td></td>
</tr>
</tbody>
</table>

### 20.00 EANO X Evening at Palais de la Bourse

## Sunday, September 9, 2012

### 08.00–09.00

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Callelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00–11.00</td>
<td>EANO Plenary Session: A. Metabolism</td>
<td>EANO Plenary Session: B. Immunotherapy</td>
<td>EANO Plenary Session: C. Tumor Angiogenesis / Angiogenic agents</td>
</tr>
<tr>
<td>11.00–11.30</td>
<td>Coffee break</td>
<td>Coffee break</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.30–12.00</td>
<td>Special Lecture: EORTC BTG: Clinical studies updates</td>
<td></td>
<td>Update in Neuro-Oncology</td>
</tr>
<tr>
<td>12.00–13.00</td>
<td>Keynote Lecture: Signaling pathways and response to treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00–14.00</td>
<td>Closing remarks, Welcome to EANO XI 2014 in Turin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room Callelongue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09.00-09.30</strong></td>
<td>Educational Day „Clinical trials: from target identification to patient benefit“</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09.30-10.00</strong></td>
<td>Access to tumor tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10.00-10.30</strong></td>
<td>Screening for a target</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10.30-10.30</strong></td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10.30-11.00</strong></td>
<td>First clinical steps of a drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11.00-11.30</strong></td>
<td>Testing a target Preclinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11.30-12.30</strong></td>
<td>Translational studies in phases I-II</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12.30-12.30</strong></td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12.30-13.30</strong></td>
<td>Part 2: Clinical trials: Optimizing phases II and III for the future</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13.30-14.30</strong></td>
<td>Phases II studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14.30-15.30</strong></td>
<td>End point in Phases III</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15.30-16.00</strong></td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16.00-17.00</strong></td>
<td>Quality of life issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>17.00-17.30</strong></td>
<td>Late toxicities in patients with brain tumor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Part 1: Clinical trials: from target selection to early development phases**

- **Access to tumor tissue**
  Phenotypic and molecular heterogeneity in gliomas: shifting the paradigm in diagnosis strategy, *P. Metellus, Marseille (FR)*; *D. Figarella-Branger, Marseille (FR)*

- **Screening for a target**
  Selected screening: Adrenomeduline as a new target in GBM, *L. Ouafik, Marseille (FR)*

- **Testing a target Preclinical**
  In vivo models, *E. Huillard, Paris (FR)*

- **Coffee break**

- **First clinical steps of a drug**
  Phases I in glioma, *J-C. Soria, Villejuif (FR)*

- **Translational studies in phases I-II**
  Predictive molecular markers in phases II studies, *J-Y. Blay, Lyon (FR)*

- **Lunch break**

- **Part 2: Clinical trials: Optimizing phases II and III for the future**

- **Phases II studies**
  Do we need alternative design for phases II in oncology?, *F. Bonnetain, Dijon (FR)*

  From positive phase II to negative phase III: Lessons from the past in glioma *M. Weller, Zürich (CH)*

- **End point in Phases III**
  Survival: the gold end-point for phases III, *M. van den Bent, Rotterdam (NL)*

  Neurological status and Clinical benefit as new objective?, *O. Chinot, Marseille (FR)*

- **Coffee break**

- **Quality of life issues**
  How to integrate QOL and cognition in phases III studies, *M. Klein, Amsterdam (NL)*

  How do we interpret Quality of Life data in Neuro-Oncology Clinical Trials? *J-C. Buckner, Rochester (US)*

- **Late toxicities in patients with brain tumor**
  How to analyze late toxicities in brain tumors, *D. Ricard, Paris (FR)*
Time | Room Riou
--- | ---
14.00-17.00 | **News & views basic science**  
**Chair:** W. Grisold, Vienna (AT)  
Epigenetics, *J. Costello, San Francisco* (US)  
Brain tumor stem cells, *J. Lathia, Cleveland* (US)  
Immunotherapeutic approaches, *M. Platten, Heidelberg* (DE)  
Brain tumor mouse models, *L. Parada, Dallas* (US)

Time | Room Callelongue
--- | ---
17.45-18.45 | **Satellite Symposium Merck Serono**  
Welcome drinks 17.30  
**Integrins: a novel target for brain cancer therapy**  
**Chair:** M. Weller, Zürich (CH)  
17.45-17.50 | Welcome, *M. Weller, Zürich* (CH)  
17.50-18.00 | Significance of integrin biology in Neuro-Oncology, *M. Weller, Zürich* (CH)  
18.00-18.40 | Cancer invasion, plasticity and integrin function: towards therapeutic targeting of cancer resistance, *P. Friedl, Nijmen* (NL)  
18.40-18.45 | Discussion and closing remarks, *M. Weller, Zürich* (CH)

**20.00 - 21.30 EANO Networking Event**

**Thursday, September 6, 2012**

at the Cercle Mixte de Garnison – Fort Ganteaume  
Start: 20.00 hrs

*Don't miss this opportunity to network, meet seasoned professionals and newcomers, and reunite with friends and colleagues!*

The Networking Event will take place at Cercle Mixte de Garnison – Fort Ganteaume, an old military building constructed under Louis XIV. Located in the very city center of Marseille overlooking the Mediterranean Sea, you will enjoy a beautiful view while being served fingerfood and drinks.

Free for registered participants.  
Please note that advance registration is mandatory in order to receive a ticket!  
Limited attendance!  

**Address:** Cercle Mixte de Garnison, Fort Ganteaume, 2 boulevard Charles Livon,  
13007 Marseille  
See map on page 4
**SCIENTIFIC PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room Riou</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nursing Research and Care Programme</strong></td>
<td><strong>EONS APPROVED EVENT</strong></td>
</tr>
<tr>
<td><strong>FRIDAY, SEPTEMBER 7</strong></td>
<td></td>
</tr>
<tr>
<td>09.00-09.10</td>
<td>Welcome</td>
</tr>
</tbody>
</table>
| 09.10 | Results Survey on Psychosocial Care in Europe  
*H. Zwinkels, The Medical Center Haaglanden, Den Haag, The Netherlands* |
| 09.10-09.40 | Purpose and effectiveness of rehabilitation for glioma patients?  
*A. McCartney, Wisdom Hospice, Medway Community Healthcare, UK* |
| 09.40-10.10 | Speech and swallowing problems in Glioma patients  
*T.M.A. Kamphuis, The Medical Center Haaglanden, Den Haag, The Netherlands* |
| 10.10-10.40 | Neurocognitive and psychological disorders in glioma patients  
*E. Habets, The Medical Center Haaglanden, Den Haag, The Netherlands* |
| 10.40-11.00 | Coffee break |
| 11.10-11.40 | Middle knowledge: To know and not to know  
*P. Salander, Umeå University, Sweden* |
| 11.40-12.10 | Emergencies and acute problems in glioma patients  
*S. McNamara, Western General Hospital Edinburgh, UK* |
| 12.10-12.40 | Multidisciplinary decisionmaking in palliative care for patients with brain tumours  
*G. Hesselmann, Universitair Medisch Centrum Utrecht, The Netherlands* |
| 12.40-13.40 | Lunch break |
| 13.40-14.10 | Psychosocial support for patients and partners  
*M. Gross, Hôpital Timone Adults, Hôpitaux de Marseille, France* |
| 14.10-14.40 | Education and Cancer Care disparities in Europe  
*Erik van Muilekom, EONS President Elect, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital* |
| 14.40-15.10 | Supportive and Palliative Care for High Grade Glioma Patients  
*J. Fleming, Waterford Regional Cancer Hospital, Ireland* |
| 15.10-15.30 | Coffee break |
| 15.30-16.00 | Palliative care in the end of life phase  
*A. Pace, National Cancer Institute Regina Elena, Rome, Italy* |
| 16.00-16.30 | Ethical decision-making in treatment of brain tumour patients  
*S. Kerrigan, Western General Hospital Edinburgh, UK* |
| 16.30-17.00 | Role and support of caregivers  
*K. Oliver, International Brain Tumour Alliance (IBTA), UK* |
| 17.00-17.30 | Discussion Starting point the Brain Tumour Patient Charter of Rights  
*and drinks & bites thereafter* |
11

FRIDAY, SEPTEMBER 7

SCIENTIFIC PROGRAMME

Time | Auditorium | Calelongue | Les Goudes 2
--- | --- | --- | ---
08.00-09.00 | Meet The Experts Session: A. Metastases Chair: A. Hottinger, Geneva (CH) Role of systemic therapy in patients with brain mets R. Stupp, Lausanne (CH) Changing role of radiotherapy and radiosurgery in the treatment of brain metastases M. Brada, London (UK) WBRT after local treatment? A. Sofielli, Turin (IT) Current trials: E. Levine M. Preusser, Vienna (AT) | Meet The Experts Session: B. Symptom management and palliative care Chair: J. Fleming, Dublin (IRL) Symptoms and problems in the end of life phase M. Taphoorn, Amsterdam (NL) Optimization of anticoagulative treatment A. Smits, Uppsala (SE) Optimal antiedematous treatment P. W. E. Zurch (CH) Palliative care A. Pace, Rome (IT) This session is kindly supported by MSD | Meet The Experts Session: C. New imaging techniques Chair: L. Bello, Milan (IT) What is the proven role of perfusion/DWI and should I use it? M. Smits, Rotterdam (NL) What is the proven role of PET and should I use it for decision making with cytotoxic therapies? A. Jacobs, Münster (DE) This session is kindly supported by Merck Serono

Time | Auditorium | Calelongue | Les Goudes 2
--- | --- | --- | ---
**SCIENTIFIC PROGRAMME**

**FRI**

**11.00-13.00**

**Immunotherapy and Biomarkers**

**Chair:** A. Carpentier, Paris (FR)

**Oral presentations**

O.22 A First In Man Phase I Trial of P.1500 (A Novel Multi-Peptide Vaccine) Plus GM-CSF In Patients With Newly Diagnosed Glioblastoma - Design And Preliminary Results of a Cancer Research UK Study


O.23 IDH1 mutation: immunotherapy for malignant glioma?

T. Schumacher, F. Sahm, A. von Deimling, W. Wick, M. Platten

O.24 Characterization of brain tumor-infiltrating cells and comparison with the peripheral immune status

H. Ardon, C. Ewelt, D. Gûnes, J. W. Müller, D. De Vleeschouwer, W. Stummer

O.25 Prognostic or predictive value of MGMT promoter methylation in malignant gliomas depends on IDH1 mutations


O.26 Circulating microvesicles in serum: could they serve as a new diagnostic tool for GBM patients?


O.27 N-myc downstream regulated gene 1 controls tumourigenicity and chemoresistance in the hypoxic niche of glioblastoma


O.28 The T genotype of the MGMT promoter (rs17801998) and the enhancement SNP is associated with promoter methylation and longer survival in patients with glioblastoma

K. L. McDonald, R. Rapkins, L. Zhou, M. Hitchins

**Oral Posterpresentations**

P.030 Dilofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model


P.051 Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens

A. Ilhan-Mutlu, A. Wohrer, A. S. Berghoff, G. Widhalm, C. Marosi, L. Wagner, M. Preusser

11.00-13.10

**Non-glial Tumors and Imaging**

**Chair:** R. Soffietti, Turin (IT)

**Oral presentations**

O.30 Recurrent high-grade meningioma: long term results of a phase II trial with somatomedin analogue therapy

M. Simò, M. Macià, G. Plans, C. Majós, M. Gil, C. Izuquierdo, R. Velasco, J. Bruna

O.31 A low outcome of dose-dense oral etoposide treatment in refractory and recurrent central nervous system germ cell tumours


O.32 Combined systemic polychemotherapy and intrathecal treatment with liposomal cytarabine in patients with primary CNS lymphoma ≥ 60 years: Results of a Phase II trial


O.33 Presentation, Diagnostics and Treatment of Primary Lepptomeningeal Lymphoma: An International Primary CNS Lymphoma Collaborative Group Series


O.34 MRI-based vessel function maps for high resolution differentiation between tumor and non-tumoral tissues in brain tumor patients


O.35 Susceptibility Weighted Imaging Predicts Progressive Disease in Patients with Recurrent Glioblastoma Treated with Bevacizumab

A. Radbruch, L. Kramp, B. Wiestler, S. Heiland, W. Wick, M. Bendszus

O.36 FDG-PET predicts survival in recurrent high grade gliomas treated with bevacizumab and irinotecan

C. Colavolpe, O. Chinot, A. S. Berghoff, M. Buchfelder, K. Roessler

O.37 Characterization of the inflammatory response to solid cancer metastases in the human brain

A. S. Berghoff, H. Lassmann, R. Hörfberger, M. Preusser

O.38 Targeting refractory pilocytic astrocytomas by Celecoxib and fluorastatin association


11.00-13.00

**Les Goudes 2**

**Presented Poster Discussion Part 1: Advances in Neurosurgery for Brain Tumor**

**Part 2: Advances in Radiotherapy for Brain Tumors**

**Chairs:** J. Tonn, Munich (DE)

**Presented by Colin Watts**

P.268 Discordance between operative electrostimulation mapping and presurgical neuroimaging of language and motor function: a meta-analysis

Zwiderman, A. Hillebrand, C. J. Stum, W. P. Vandertop, P. C. De Witt Hamer

P.270 The determination of intra-operative NAD(P)H redox status in patients with brain tumours

D. G. Ngoya, D. Tennant, A. A. Olayien, C. Cruickshank

P.269 The impact of intraoperative resection control in brain tumor surgery

C. Senft, F. Gessler, M. Mittelbronn, S. Dützmann, K. Franz, E. Hattingen, V. Seifert

P.271 Brain mapping with intra-operative neurophysiological monitoring and minimally invasive craniotomies: are these two techniques mutually exclusive?

G. Carrabba, G. Bertani, F. Colognianian, G. Ardolino, M. Galiano, L. Conte, M. Caroli, S. M. Gaini

P.266 Initial experience with an intraoperative Magnetic Resonance equipment in the Spanish Public Health Care System

M. Brell, P. Roldán, E. Gonzalez, J. Ibáñez

**Presented by C. Dirven**

P.264 Surgical management of tumours causing epilepsy located in eloquent brain areas using functional neuronavigation and intraoperative MR imaging

B. Sommer, P. Grumich, H. M. Hamer, I. Blümcke, R. Coras, M. Buchfelder, K. Roessler

P.272 S-ALA guided resection of malignant glioma: a single Institution experience

P. Oppido, C. Carapella, A. Pampili, A. Vidiri, A. Pace

P.265 Intraoperative identification of motor cortex using multimodal neuroimaging in surgery of intra-axial brain tumors

V. D. Rozumenko, A. V. Rozumenko

P.187 Regardless of the molecular status, neoadjuvant chemotherapy can optimize the extent of resection of World Health Organization Grade II Gliomas

M. Blonski, J. Paullid, C. Gozé, E. Mandoulet, P. Beaucamps, M. Baron, D. Fontaine, A. Darlix, H. Duffau, L. Taillandier
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Calelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00-14.00</td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.15</td>
<td>Presidential address: Wolfgang Grisold, President EANO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15-15.45</td>
<td>Plenary session: Brain Tumor Microenvironment Chair: M. Weller, Zurich (CH)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glioma stem cells and radioresistance, A. Chalmers, Glasgow (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The angiogenic niche, T. Acker, Giessen (DE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Where is the role in the clinic?, C. Watts, Cambridge (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Les Goudes 1, Exhibitions Area</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.45-17.00</td>
<td>Coffee and Poster viewing with presenters</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TOPICS:**
- Cell biology and signalling
- Epidemiology
- Quality of life
- Immunology and immunotherapy
- In vitro / in vivo models
- Predictive biomolecular markers
- New drug delivery methods
- Neuroimaging of brain tumours
- Glioblastoma multiforme and Anaplastic gliomas

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00-18.00</td>
<td>Keynote lecture</td>
</tr>
<tr>
<td>Chair: B. Melin, Umeå (SE)</td>
<td>Epidemiology/Risk Factors, M. Bondy, Houston (US)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room Callelongue</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.00-19.30</td>
<td>Satellite Symposium MSD</td>
</tr>
<tr>
<td>Current Perspectives in CNS Malignancies: Updates and LEARNINGS</td>
<td>Chair: M. van den Bent, Rotterdam (NL)</td>
</tr>
<tr>
<td>18.00-18.05</td>
<td>Introduction and Objectives, M. van den Bent, Rotterdam (NL)</td>
</tr>
<tr>
<td>08.05-18.25</td>
<td>Perspectives on Treatment for Elderly Patients with GBM, W. Wick, Heidelberg (DE)</td>
</tr>
<tr>
<td>18.25-18.45</td>
<td>Updates From EORTC 26951, M. van den Bent, Rotterdam (NL)</td>
</tr>
<tr>
<td>18.45-19.05</td>
<td>Key Learnings From RTOG 9402, M. Gilbert, Houston (US)</td>
</tr>
<tr>
<td>19.05-19.20</td>
<td>Discussion: Treatment Options for Anaplastic Oligodendroglioma, M. Gilbert, Houston (US), M. van den Bent, Rotterdam (NL)</td>
</tr>
<tr>
<td>19.20-19.30</td>
<td>Panel Discussion and Closing Remarks, Faculty</td>
</tr>
<tr>
<td>Time</td>
<td>Auditorium</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>09.00-10.00</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Time</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Time</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Time</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10.30-12.30</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Glioma-Clinical studies and Neuroimaging</strong></td>
<td><strong>Chair:</strong> O. Chinot</td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.39</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.40</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.47</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.48</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.49</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.50</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.51</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>O.52</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Presented by W. Smits</strong></td>
<td><strong>Presented Poster Discussion Paraneoplastic Syndromes, PCNSL and other non-glial tumors</strong></td>
</tr>
<tr>
<td><strong>P.076</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Non-invasive assessment of the invasive microenvironment of glioblastomas: a multi-modal imaging study</strong></td>
<td><strong>Chair:</strong> M. Riva</td>
</tr>
<tr>
<td><strong>D. Filimonov, V. Symonian</strong></td>
<td><strong>Lessons from chemotherapy use in high-grade childhood brain tumors</strong></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Presented by W. Smits</strong></td>
<td><strong>Lessons from chemotherapy use in high-grade childhood brain tumors</strong></td>
</tr>
<tr>
<td><strong>P.076</strong></td>
<td></td>
</tr>
<tr>
<td><strong>D. Filimonov, V. Symonian</strong></td>
<td><strong>Non-invasive assessment of the invasive microenvironment of glioblastomas: a multi-modal imaging study</strong></td>
</tr>
<tr>
<td><strong>Presented by M. Smits</strong></td>
<td><strong>Non-invasive assessment of the invasive microenvironment of glioblastomas: a multi-modal imaging study</strong></td>
</tr>
<tr>
<td><strong>P.076</strong></td>
<td></td>
</tr>
<tr>
<td><strong>D. Filimonov, V. Symonian</strong></td>
<td><strong>Non-invasive assessment of the invasive microenvironment of glioblastomas: a multi-modal imaging study</strong></td>
</tr>
</tbody>
</table>
12.30 - 10.30

SCIENTIFIC PROGRAMME

www.eano.eu

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Callelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
</table>
| 10.30-12.30 |            |             | **P.232** Radiosurgery for brain metastases: specific indications for Gamma Knife in lieu of Linac in a single center using both methods  
*M. Levivier, V. Magaddino, L. Negretti, C. Tuleasca, R. Moeckli* |
|          |            |             | **P.227** Prognostic impact of flow cytometry quantification of EpCAM+ cells in the cerebrospinal fluid of patients with leptomeningeal carcinomatosis  
|          |            |             | **P.227** Prognostic impact of flow cytometry quantification of EpCAM+ cells in the cerebrospinal fluid of patients with leptomeningeal carcinomatosis  
| 12.30-13.30 | Lunch break |            |              |
| 13.30-15.00 | Auditorium |             | **P.240** Open-label, randomized phase II, of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with standard WBRT in breast cancer patients with newly diagnosed brain metastasis: the XERAD trial  
*A. Carpentier, K. Peignaux, H. Bourgeois, F. Fauchon, J. Prevost, D. Azria, A. Toulemonde, A. Lortholary, J. Bonneterre, C. Hennequin* |
| 15.00-15.45 | Les Goudes 1, Exhibitions Area | **P.242** Improvement of Overall Survival in Patients with Brain Metastasis. An Analysis of 2003 and 2010 Cohort in a Community Oncology Center  
*T. Lam, F. Wong, W. Sze, S. Tung* |

**Plenary sessions: Optimizing local non-surgical treatment in glioma**

**Chair:** U. Abacioglu, Istanbul (TR)

Stretching high-precision radiotherapy to an invasive disease, *B. Baumert, Maastricht (NL)*

Integrin-mediated radiosensitization, *E. Cohen-Jonathan Moyal, Toulouse (FR)*

Targeted peptides & nanoparticles, *S. Chang, San Francisco (US)*

**Coffee and Poster viewing with presenters TOPICS:**

10. Low grade gliomas ................................................................. P.175-191
11. Pediatric brain tumours ......................................................... P.192-203
12. Meningiomas ........................................................................... P.204-216
13. Spinal cord tumours .............................................................. P.217-222
14. Brain and leptomeningeal metastases ..................................... P.223-247
15. Neurotoxicity and neuroprotection ......................................... P.248-251
16. Paraneoplastic neurological syndromes ................................... P.252-254
17. Supportive and palliative care ............................................... P.255-259
18. Primary central nervous system lymphoma (PCNSL) ............... P.260-263
20. New developments in radiotherapy ......................................... P.273-281
21. Miscellaneous ......................................................................... P.282-299
### SCIENTIFIC PROGRAMME

#### SATURDAY, SEPTEMBER 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.45-16.45</td>
<td><strong>Keynote lecture</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> P. Collins, Cambridge (UK)</td>
</tr>
<tr>
<td></td>
<td><strong>Epigenetics,</strong> J. Costello, San Francisco (US)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.45-17.15</td>
<td><strong>EANO General Assembly</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Room Callelongue</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.15-18.45</td>
<td><strong>Satellite Symposium Prime Oncology</strong></td>
</tr>
<tr>
<td>17.15</td>
<td><strong>Welcome drinks 16.45</strong></td>
</tr>
<tr>
<td>17.15</td>
<td><strong>Evaluating the Role of Emerging Agents in Newly Diagnosed Glioblastoma</strong></td>
</tr>
<tr>
<td>17.15</td>
<td>Welcome and introduction, O. Chinot, Marseille (FR), W. Wick, Heidelberg (DE)</td>
</tr>
<tr>
<td>17.20</td>
<td>Clinical opinion poll, O. Chinot, Marseille (FR)</td>
</tr>
<tr>
<td>17.25</td>
<td>Standards of care and goals of therapy for newly diagnosed glioblastoma, M. Weller, Zürich (CH)</td>
</tr>
<tr>
<td>17.45</td>
<td>Clinical opinion poll, O. Chinot, Marseille (FR)</td>
</tr>
<tr>
<td>17.50</td>
<td>Rationale for novel therapies in newly diagnosed glioblastoma, M. van den Bent, Rotterdam (NL)</td>
</tr>
<tr>
<td>18.05</td>
<td>Clinical opinion poll, O. Chinot, Marseille (FR)</td>
</tr>
<tr>
<td>18.10</td>
<td>Emerging therapies for newly diagnosed glioblastoma: Evaluating the data, W. Wick, Heidelberg (DE)</td>
</tr>
<tr>
<td>18.35</td>
<td>Symposium “pearls”: Where do we go from here?, W. Wick, Heidelberg (DE)</td>
</tr>
<tr>
<td>18.45</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**20.00 – 24.00 EANO X Party at Palais de la Bourse**

*Saturday, September 8, 2012*

Start: 20.00 hrs

This neo-classical palace is located on the Canebière, close to the Vieux-Port. Designed by architect Pascal Coste for Napoleon III, it houses Marseilles’ Chamber of Commerce and Industry, founded in 1599, and the Maritime Museum. The façades of this splendid edifice feature an array of sculptures which were constructed to celebrate Marseilles’ Golden Age of navigation and commerce.

At the **EANO X Evening** you will be enjoying a seated dinner in the magnificent setting of the Palais de la Bourse while enjoying the company of your colleagues and friends, this evening will be one to treasure — make sure not to miss it!

**for regular participants** € 80.– per person

**for PhD students, residents, nurses, trainees** € 40.– per person

*(only applicable with adequate fee)*

*Please note that seats are limited and advance registration is mandatory in order to receive a ticket!*

**Dress code:** formal

**Address:**

Palais de la Bourse

9 place du Général de Gaulle

13001 Marseille

See map on page 4
### SCIENTIFIC PROGRAMME

#### SUNDAY, SEPTEMBER 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Callelongue</th>
<th>Les Goudes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td><strong>Update in Neuro-Oncology</strong>&lt;br&gt;<strong>Chair:</strong> K. Aldape, SNO, R. Soffietti, EANO&lt;br&gt;What is the right place for bevacizumab: at recurrence or in upfront treatment?, <em>S. Chang, San Francisco (US)</em>&lt;br&gt;Biology of resistance to antiangiogenic therapies, <em>M. Weller, Zurich (CH)</em>&lt;br&gt;Is there a role for dose-dense temozolomide?, <em>M. Gilbert, Houston (US)</em>&lt;br&gt;Outcome predictors in low-grade and anaplastic gliomas, <em>W. Wick, Heidelberg (DE)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-11.00</td>
<td><strong>EANO Plenary Session A. Metabolism</strong>&lt;br&gt;<strong>Chair:</strong> S. Niclou, Luxembourg (L)&lt;br&gt;Antitumor targets in the glycolytic metabolism <em>P. Sonveaux, Louvain (BE)</em>&lt;br&gt;Metabolic state of glioma cells <em>M. Sanson, Paris (FR)</em>&lt;br&gt;Novel ways to target metabolism in brain tumors <em>S. Niclou, Luxembourg (L)</em></td>
<td><strong>EANO Plenary Session B. Immunotherapy</strong>&lt;br&gt;<strong>Chair:</strong> M. Platten, Heidelberg (DE)&lt;br&gt;Cell-based approaches <em>S. van Gool, Leuven (BE)</em>&lt;br&gt;Emerging immune therapeutics targeting glioma-mediated immune suppression A. Heimberger, Houston (US)&lt;br&gt;EGFRvIII as a target in clinical trials <em>M. Weller, Zürich (CH)</em></td>
<td><strong>EANO Plenary Session C. Tumor Angiogenesis / Angiogenic agents</strong>&lt;br&gt;<strong>Chair:</strong> R. Soffietti, Turin (IT)&lt;br&gt;Angiogenesis and invasiveness R. Bjerkvig, Bergen (NO)&lt;br&gt;In vivo imaging of responses to VEGF therapy <em>F. Winkler, Heidelberg (DE)</em>&lt;br&gt;Clinical perspective – Europe M. van den Bent, Rotterdam (NL)&lt;br&gt;Clinical perspective – US T. Batchelor, Boston (US)*</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td><em>Coffee break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-12.00</td>
<td><strong>Special Lecture</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>EORTC BTG: Clinical studies updates</strong>, <em>W. Wick, Heidelberg (DE)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-13.00</td>
<td><strong>Keynote lecture</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> R. Grant, Edinburgh (UK)&lt;br&gt;Signaling pathways and response to treatment, <em>T. Würdinger, Amsterdam (NL)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Closing remarks and welcome to EANO XI 2014 in Turin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Meetings
As per date of printing.

**Thursday, September 6, 2012**  
- 12.00–14.00  EANO Board Meeting (closed Meeting)
- 14.00–15.00  CI-Perinoms Study Meeting
- 16.00–17.30  EANO Scientific Committee & Executive Board Meeting (closed Meeting)

**Friday, September 7, 2012**  
- 09.00–11.00  Patient Organisation Meeting (closed Meeting)
- 11.00–12.30  Cochrane Neuro-Oncology Group
- 13.00–14.00  Industry Lunch Meeting (closed Meeting)
- 14.30–16.30  EANO Executive Board & National Societies (closed Meeting)
- 16.30–18.00  North Africa & Eastern Europe

**Saturday, September 8, 2012**  
- 09.00–10.00  Neuro-Oncology Editorial Board Meeting (closed Meeting)
- 10.00–11.30  European Network on End-On-Life Research in Neuro-Oncology
- 12.00–13.00  Award Walking Lunch (closed Meeting)
- 13.00–15.00  SANO
- 15.00–16.30  SNO & Japanese Society & EANO Executive Board (closed Meeting)

**Open to all members**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.45–17.15</td>
<td>EANO General Assembly</td>
</tr>
</tbody>
</table>

Room Sormiou

Room Les Goudes 2
Corporate Satellite Symposia – open to all participants

Thursday, September 6, 2012
17.45–18.45 Satellite Symposium Merck Serono Room Callelongue
Integrins: a novel target for brain cancer therapy
Chair: M. Weller, Zürich (CH)
Welcome drinks 17.30
17.45–17.50 Welcome, M. Weller, Zürich (CH)
17.50–18.00 Significance of integrin biology in Neuro-Oncology, M. Weller, Zürich (CH)
18.00–18.40 Cancer invasion, plasticity and integrin function: towards therapeutic targeting of cancer resistance, P. Friedl, Nijmegen (NL)
18.40–18.45 Discussion and closing remarks, M. Weller, Zürich (CH)

Friday, September 7, 2012
18.00–19.30 Satellite Symposium MSD Room Callelongue
Current Perspectives in CNS Malignancies: Updates and LEARNINGS
Chair: M. van den Bent, Rotterdam (NL)
18.00–18.05 Introduction and Objectives, M. van den Bent, Rotterdam (NL)
18.05–18.25 Perspectives on Treatment for Elderly Patients with GBM, W. Wick, Heidelberg (D)
18.25–18.45 Updates From EORTC 26951, M. van den Bent, Rotterdam (NL)
18.45–19.05 Key Learnings From RTOG 9402, M. Gilbert, Houston (US)
19.05–19.20 Discussion: Treatment Options for Anaplastic Oligodendroglioma, M. Gilbert, Houston (US); M. van den Bent, Rotterdam (NL)
19.20–19.30 Panel Discussion and Closing Remarks, Faculty

Saturday, September 8, 2012
17.15–18.45 Satellite Symposium Prime Oncology Room Callelongue
Evaluating the Role of Emerging Agents in Newly Diagnosed Glioblastoma
Welcome drinks 16.45
17.15–17.20 Welcome and introduction, O. Chinot, Marseille (FR); W. Wick; Heidelberg (DE)
17.20–17.25 Clinical opinion poll, O. Chinot, Marseille (FR)
17.25–17.45 Standards of care and goals of therapy for newly diagnosed glioblastoma, M. Weller, Zürich (CH)
17.45–17.50 Clinical opinion poll, O. Chinot, Marseille (FR)
17.50–18.05 Rationale for novel therapies in newly diagnosed glioblastoma, M. van den Bent, Rotterdam (NL)
18.05–18.10 Clinical opinion poll, O. Chinot, Marseille (FR)
18.10–18.35 Emerging therapies for newly diagnosed glioblastoma: Evaluating the data, W. Wick, Heidelberg (DE)
18.35–18.45 Symposium "pearls": Where do we go from here?, W. Wick, Heidelberg (DE)
18.45 Adjourn
Publication
Please note that your work will be published in the September issue of Neuro-Oncology.

Programme Changes
The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances.

Session types
Oral Sessions: oral presentation of 12 minutes taking place in a lecture hall, presented by one of the author of a submitted and selected abstract, presentation numbers starting with O.
Oral Poster Presentations: oral presentation of 4 minutes taking place in a lecture hall, presented by one of the author of a submitted and selected abstract, presentation numbers starting with P.
Presented Poster Discussions: oral presentation of combined data from selected posters presented by a senior speaker, presentation number starting with P.
Poster Sessions: presentation of posters within the exhibition, presentation numbers starting with P.

ORAL PRESENTATIONS

Slide Preview
It is essential that you load and view your presentations in the preview center preferably 6 hours before your talk, but no later than 2 hours in advance. The preview center is situated in Room Morgiou.

Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.
- For oral presentations: **12 minutes slots** a maximum of **10 minutes speaking time**.
- For oral poster presentations: **4 minutes speaking time**
Please rehearse your talk to make sure it will fit comfortably into the available time. Please note that, as a rule, presenters can show a (final) slide with all acknowledgements, however, in view of the short time available, names cannot be read to the audience.
Make yourself known to the chairpersons and/or the room assistant in your session room before the beginning of the session.

Projection and Technical Setting
- All rooms will be equipped with data-projection (no slides).
- It is essential that you load and view your presentation in the slide preview room preferably 6 hours before your talk, but not later than 2 hours in advance.
- The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Should you absolutely have to use your own laptop or notebook, please contact the congress office in advance.
- Please bring a USB-stick, CD-ROM or floppy disk all formatted for Windows® (PC). You may want to carry a second disk/CD as a back-up in case there is any insoluble technical problem.
- File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows XP®)
- Preferred Resolution: XGA (1024 x 768 pixel)
PRESENTED POSTER DISCUSSION

This is a new type of session introduced by the scientific committee of the 10th Meeting of the European Association of NeuroOncology where a senior speaker will present the data combined with data from other posters in a short 30 minutes oral presentation.

Kindly note, that if you have been informed that your poster has been accepted for a presented poster discussion session, you are NOT presenting this data yourself!

Preparation
In order for your poster to be presented, you have been asked to please prepare the following:
- A Power Point Presentation (maximum 2-3 slides) of your poster. These slides will be used by the senior speaker to present your data during the “Presented Poster Discussion” session.
- A poster that will be mounted onsite in the poster exhibition. The surface on the poster board will be 90 cm width x 130 cm height (approx. 35 x 51 inches) and posters should be in upright format.

POSTER PRESENTATIONS

Format
The usable surface on the poster board will be 90 cm width x 130 cm height (approx. 35 x 51 inches). Only pins can be used to mount posters. Material will be made available.

Poster mounting and removal
Posters will be on display from Thursday, September 6, (09.00 hrs) to Sunday, September 9, 2012, (11.30 hrs).
Poster mounting will be possible on: Friday, September 7, 2012, from 09.00 - 15.00 hrs.
Removal will be possible on: Sunday, September 9, 2012, from 11.30 hrs - 13.00 hrs.

Your poster board number has been sent to you in the information email for poster presenters. You will also find this number in the EANO 2012 – Book of Abstract, that you will receive at the conference.

The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Please note that posters not removed by Sunday, September 9, 2012 by the end of the closing lecture will be taken down by the staff of the conference center and will not be stored or sent to the authors after the meeting.

Presence at Posters
In order to enable discussion and interaction with other participants, we request you or one of your group to be at your poster board between:

On Friday, September 7, 2012 from 15.45 – 17.00 for the following posters topics:
01. Cell biology and signalling 13
02. Epidemiology
03. Quality of life
04. Immunology and immunotherapy
05. In vitro / in vivo models
06. Predictive biomolecular markers
07. New drug delivery methods
08. Neuroimaging of brain tumours
09. Glioblastoma multiforme and Anaplastic gliomas
On **Saturday, September 8, 2012 from 15.00 – 15.45** for the following posters topics:

10. Low grade gliomas  
11. Pediatric brain tumours  
12. Meningiomas  
13. Spinal cord tumours  
14. Brain and leptomeningeal metastases  
15. Neurotoxicity and neuroprotection  
16. Paraneoplastic neurological syndromes  
17. Supportive and palliative care  
18. Primary central nervous system lymphoma (PCNSL)  
19. New developments in surgery  
20. New developments in radiotherapy  
21. Miscellaneous

If this is not possible, please leave a note on your poster board detailing the times when you will be present at the board.

**POSTER TOPICS**

01. Cell biology and signalling .............................................................P.001-013  
02. Epidemiology ..............................................................................P.014-017  
03. Quality of life ..............................................................................P.018-027  
04. Immunology and immunotherapy ...................................................P.028-035  
05. In vitro / in vivo models ................................................................P.036-044  
06. Predictive biomolecular markers ...................................................P.045-052  
07. New drug delivery methods .............................................................P.053-055  
08. Neuroimaging of brain tumours .....................................................P.056-079  
09. Glioblastoma multiforme and Anaplastic gliomas .........................P.080-174  
10. Low grade gliomas .......................................................................P.175-191  
11. Pediatric brain tumours .................................................................P.192-203  
12. Meningiomas ...............................................................................P.204-216  
13. Spinal cord tumours .....................................................................P.217-222  
14. Brain and leptomeningeal metastases .............................................P.223-247  
15. Neurotoxicity and neuroprotection .................................................P.248-251  
16. Paraneoplastic neurological syndromes ...........................................P.252-254  
17. Supportive and palliative care .........................................................P.255-259  
18. Primary central nervous system lymphoma (PCNSL) .........................P.260-263  
20. New developments in radiotherapy .................................................P.273-281  
21. Miscellaneous ..............................................................................P.282-299
Thursday, September 6, 2012
NETWORKING EVENT
at the Cercle Mixte de Garnison – Fort Ganteaume
Start: 20.00 hrs

The Networking Event will take place at Cercle Mixte de Garnison – Fort Ganteaume, an old military building constructed under Louis XIV. Located in the very city center of Marseille overlooking the Mediterranean Sea, you will enjoy a beautiful view while being served fingerfood and drinks.

**Free for registered participants.**
Please note that advance registration is mandatory in order to receive a ticket!
Limited attendance!

Address:
Cercle Mixte de Garnison
Fort Ganteaume
2 boulevard Charles Livon
13007 Marseille
See map on page 4

Saturday, September 8, 2012
EANO X EVENING
at Palais de la Bourse
Start: 20.00 hrs

The EANO X Evening will take place in the reception hall on the ground floor of the building. You will be enjoying a seated dinner in the magnificent setting of the Palais de la Bourse while enjoying the company of your colleagues and friends, this evening will be one to treasure — make sure not to miss it!

**for regular participants:**
€ 80,– per person

**for PhD students, residents, nurses, trainees:**
€ 40,– per person
(only applicable with adequate fee)

Please note that seats are limited and advance registration is mandatory in order to receive a ticket!
Limited Attendance!
Dress code: formal

Address:
Palais de la Bourse
9 place du Général de Gaulle
13001 Marseille
See map on page 4
Badges
Participants have to collect name badges from the conference registration desk. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue. Accompanying persons and exhibitors will also receive badges to allow access to the respective areas. **Lost badges can be replaced at the registration desk. However, a handling fee of € 30.– will be charged.**

CAR PARKING
Participants may park their car in the parking lot of the Parc Chanot. Tickets cost € 4.– per day.

Certificate of Attendance
Confirmations of attendance will be issued at the registration desk.

Climate
Marseille enjoys a Mediterranean climate. Temperatures in September are generally above 20 °C (68.0 °F).

Cloakroom and Luggage
A cloakroom and luggage storage facilities are available in the congress venue.

CME CREDITS
The 10th Meeting of the European Association of NeuroOncology (EANO 2012) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

**The 10th Meeting of the European Association of NeuroOncology (EANO 2012) is designated for a maximum of 21 hours of European external CME credits.**

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The rules of the EACCME state that participants are kindly asked to fill in the feedback form included in the conference bag. It can be returned to the registration desk.

Coffee Breaks
During the session breaks refreshments (coffee, tea and water) will be served free of charge to participants wearing name badges. Coffee breaks will take place in the exhibition area.

Currency
The official currency of France is the Euro (€). 1 EURO = 1.22 USD = 0.78 GBP = 96.71 JPY = 1.20 CHF = 7.80 CNY (as per date of printing)

Drinking Water
Tap water in France is purified so it is suitable for drinking. Most people, however, prefer to drink bottled water because it tastes better and is moderately priced.
Electricity Supply
Electricity used in France is 220 Volts; frequency is 50 Hz and the plugs have two male contact points. Plan to bring an adaptor for your electrical appliances or electronic equipment using different voltage.

Exhibition Opening Hours
<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, September 6, 2012</td>
<td>08.00 – 17.30 hrs</td>
</tr>
<tr>
<td>Friday, September 7, 2012</td>
<td>08.00 – 18.00 hrs</td>
</tr>
<tr>
<td>Saturday, September 8, 2012</td>
<td>08.00 – 17.30 hrs</td>
</tr>
<tr>
<td>Sunday, September 9, 2012</td>
<td>08.00 – 13.00 hrs</td>
</tr>
</tbody>
</table>

Insurance
In registering for the EANO 2012 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance.

INTERNET
2 internet stations as well as a WIFI access will be available within the exhibition area.

Language
The official language of the congress will be English. Only the Nurses Session on Friday, September 7, 2012 will be simultaneously be translated into French. French is the official language in Marseille.

Lunch and Refreshments
Lunch tickets for lunch boxes for Thursday, Friday and Saturday are included in the registration fee but **had to be pre-ordered – they cannot be purchased on site.**

Marseille
Marseille is the second largest city in France, after Paris, with a population of 852,395. Located on the southeast coast of France on the Mediterranean Sea, Marseille is France’s largest commercial port and largest French city on the Mediterranean coast. Marseille is the capital of the Provence-Alpes-Côte d’Azur (PACA) region, as well as the capital of the Bouches-du-Rhône department. Founded in 600 b.c. by the Greek sailors of Phocaea, this great city is the oldest in France and surely the most complex. Marseille has always been a meeting place of ideas, races and civilisations. It is also a major French centre for trade and industry, with excellent transportation infrastructure (roads, sea port and airport). Today Marseilles remains a capital of southern Europe, cosmopolitan and exuberant, with its picturesque old port, its Bouillabaisse and its folklore.

Message Board
A Message Board is available in the Exhibition / Registration Area.

Pharmacies
Pharmacies are easy to identify thanks to the green cross displayed outside. Most pharmacies are open during normal trade hours, between 08:30 and 18:30hrs. Some are open until 20:00hrs. Closed on Sundays.

Poster Removal
Please see – SCIENTIFIC INFORMATION (page 23)

Preview Room
Please see – SCIENTIFIC INFORMATION (page 22)
Programme Changes – Access to Sessions
The conference organisers reserve a right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser. Programme changes will be displayed on the message board.

Public Transport
Marseille Public Transportation System (RTM) www.rtm.fr
Marseille has two Metro lines: Line 1 (blue) between Castellane and La Fourragère and Line 2 (red) between Sainte-Marguerite-Dromel and Bougainville.

Prices:
- Single tickets per journey: € 1,50
- 24 hour ticket: € 5,00
- 3 days card: € 10,50 (include unlimited travel during that period on all buses and both metro lines)
- Day card "spécial visite" EUR 5,00 (valid from the first journey until midnight, for an unlimited number of journeys on the whole city transport network).

Metro timetables:
- Monday – Thursday: 05:00 hrs – 22:30 hrs then the "fluobus" takes over till 00:35 hrs.
- Friday – Sunday: 05:00 hrs – 00:30 hrs

Tram timetable:
- 05:00 hrs - 00:30 hrs every day
www.le-tram.fr
As in many other French cities, a short-term bicycle hire scheme nicknamed "Le vélo", free for trips of less than half an hour, has recently been put in place by the city council.

Registration Desk opening hours
Thursday, September 6, 2012 08.00 – 19.00 hrs
Friday, September 7, 2012 07.00 – 18.30 hrs
Saturday, September 8, 2012 07.30 – 19.00 hrs
Sunday, September 9, 2012 07.30 – 13.30 hrs

Safety – Crime
Visitor safety is generally adequate. As in any other major European city, you can walk everywhere using common sense.

Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city. Leave them in the hotel safe during your stay. Rather, carry a photocopy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it gets lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference center.

Shops
The main commercial centre of the city intersects with the Canebière at rue St Ferréol and the Centre Bourse. The centre of Marseille has several pedestrianised zones, most notably rue St Ferréol, Cours Julien near the Music Conservatory, the Cours Honoré-d’Estienne-d’Orves off the Old Port and the area around the Hôtel de Ville.
**Smoking Policy**
The EANO 2012 is a “Non-smoking-Conference”. Please note that smoking is banned from all public buildings. Restaurants and bars may, depending on size, be declared either as “smoking” or “non-smoking” locations or have separate areas and ventilation systems.

**Staff**
Should you have any questions, congress staff will be pleased to help you. Please contact the registration desk.

**Taxis in Marseille**
Le Taxis Marseillais – Tel: +33 (0)4 91 92 92 92
Taxis Radio France – Tel: +33 (0)4 91 02 20 20

**Telephone**
For international calls to France, dial the international code followed by 0033 and the correspondent’s number without the 0. For international calls from France, dial 00 followed by your correspondent’s international code and number.

**Tourist Information**
Marseille Tourist Office
www.marseille-tourisme.com
4, La Canebière – 13001 Marseille – France
Tel: +33 (0)4 91 13 89 00
(Subway (“Métro”) Line 1: Vieux-Port Station)

**Travelling to Park Chanot by public transport**
The best way to reach Parc Chanot is to use the public transport system. From the city center (station “Vieux Port”), use the blue line (M1) in direction of “La Fourragère”. Change to the red metro line (M2) at station “Castellane” in direction of “Sainte-Marguerite Dromel”. Get off at station “Rond-Point du Prado”.

**V.A.T.**
A value-added tax (V.A.T.) of 7% (food) to 19,6% (other items) is applied to all products and services. In most cases it is included in the price. Whenever it is not included, however, it will be clearly specified.
**REGISTRATION FEES**

**Onsite registration is possible during the opening hours of the registration desk as follows:**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, September 6, 2012</td>
<td>08.00 – 19.00 hrs</td>
</tr>
<tr>
<td>Friday, September 7, 2012</td>
<td>07.00 – 18.30 hrs</td>
</tr>
<tr>
<td>Saturday, September 8, 2012</td>
<td>07.30 – 19.00 hrs</td>
</tr>
<tr>
<td>Sunday, September 9, 2012</td>
<td>07.30 – 13.30 hrs</td>
</tr>
</tbody>
</table>

**Payment received by all fees include VAT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Before June 15, 2012 (reduced rate)</th>
<th>Between June 15 and July 31, 2012 (normal rate)</th>
<th>After 01 August 2012 and on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular participants/EANO members</td>
<td>EUR 390.–</td>
<td>EUR 460.–</td>
<td>EUR 520.–</td>
</tr>
<tr>
<td>Regular participants/Non-members</td>
<td>EUR 610.–</td>
<td>EUR 680.–</td>
<td>EUR 740.–</td>
</tr>
<tr>
<td>PhD students and residents Nurses, Trainees</td>
<td>EUR 200.–</td>
<td>EUR 200.–</td>
<td>EUR 250.–</td>
</tr>
<tr>
<td>accompany persons</td>
<td>EUR 45.–</td>
<td>EUR 70.–</td>
<td>EUR 70.–</td>
</tr>
</tbody>
</table>

**Important**
The reduced registration fee is only applicable, if it has been credited to the congress account before the deadline. Registering before the respective deadlines without performing an actual payment is not sufficient to benefit from the reduction. Please note that a different fee applies for on-site registrations.

---

**EANO X Educational course September 6, 2012**

**Registration fee: EUR 165.–** If you wish to attend the Educational course, please note that it is NOT included in the registration fees of EANO 2012. The Educational course is subject to additional registration and costs. The attendance is limited. Please make sure to pre-register well in advance!

---

**What is covered by the registration fee?**

**Participants:** Admission to all scientific sessions exhibition, abstract book and programme, coffee breaks, lunch boxes on 2 days (Friday and Saturday).

**EANO X Educational course:** Admission to courses of your choice, Syllabus, Coffee breaks, Lunch box for 1 day (Thursday)

---

**Payment of the registration fees:**
to be made in advance in EUR by:

- **Bank transfer** to bank account "WMA/EANO 2012" Account number: 295 331 080 05, Bank/Routing code 20111, SWIFT/BIC: **GIBAATWWXXX**, IBAN **AT93 20111 28627496358**
  - bank name and address: Erste Bank, Alser Strasse 23, 1080 Vienna, Austria, – to avoid bank charges; please use the IBAN within the EU. Payments to be made free of charge to the beneficiary. Any bank charges will be collected on site. Clearly state the participant’s name(s).

- **Credit Card:** payments with Diners Club, Mastercard and Visa are possible. No other credit cards are accepted.

---

**Cancellations and refunds**

Notice of cancellation must be made in writing, by registered letter or fax, to the Conference Office.

Registration fees will be refunded as follows:

- **Written cancellation received:**
  - before June 16, 2012: 75% refund
  - between June 16 and July 31, 2012: 25% refund
  - after July 31, 2012: no refund

The date of the postmark or fax ID will be the basis for considering refunds. Please indicate the preferred method of reimbursement (cheque or bank transfer, incl. account number) on your written cancellation. Refunds will be made after the congress.

**Please note:** Pre-registration without payment of the registration fee is possible. The **onsite fee** will then have to be paid at the registration desk (Credit card or cash in EUR).
The European Association of NeuroOncology gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing):

in Alphabetical Order

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Archimedes Pharma, Courbevoie, France</td>
<td>2</td>
</tr>
<tr>
<td>AINO (Italian Association of Neuro-Oncology), Turin, Italy</td>
<td>16</td>
</tr>
<tr>
<td>Deutsche Hirntumorhilfe, Leipzig, Germany</td>
<td>17</td>
</tr>
<tr>
<td>EANO (European Association of Neuro-Oncology), Kaatsheuvel, Netherlands</td>
<td>14</td>
</tr>
<tr>
<td>ELEKTA Instrument, Stockholm, Sweden</td>
<td>1</td>
</tr>
<tr>
<td>IBTA (International Brain Tumor Alliance), Tadworth, United Kingdom</td>
<td>15</td>
</tr>
<tr>
<td>KRAUSE &amp; PACHERNEGG, Gablitz, Austria</td>
<td>13</td>
</tr>
<tr>
<td>medac, Wedel, Germany</td>
<td>3</td>
</tr>
<tr>
<td>MERCK Serono, Darmstadt, Germany</td>
<td>4</td>
</tr>
<tr>
<td>MSD, Whitehouse Station, United States</td>
<td>6</td>
</tr>
<tr>
<td>Novocure, Portsmouth, United States</td>
<td>12</td>
</tr>
<tr>
<td>Roche, Basel, Switzerland</td>
<td>5</td>
</tr>
<tr>
<td>VARIAN Medical Systems International, Zug, Switzerland</td>
<td>7</td>
</tr>
<tr>
<td>Wisepress, London, United Kingdom</td>
<td>8</td>
</tr>
</tbody>
</table>

Archimedes Pharma
www.archimedespharma.com

AINO
Turin, Italy

Deutsche Hirntumorhilfe
www.hirntumorhilfe.de

EANO
www.eano.eu

ELEKTA Instrument
www.elekta.com

International Brain Tumor Alliance – IBTA
www.theibta.org

KRAUSE & PACHERNEGG
www.kup.at

medac
www.medac.de

Merck Serono
www.merckgroup.com

MSD
www.merck.com

Novocure
www.novocure.com

Roche
www.roche.com

Varian Medical Systems International
www.varian.com

Wisepress
www.wisepress.com
Evaluating the Role of Emerging Agents in Newly Diagnosed Glioblastoma

A satellite symposium in conjunction with the 10th European Association of the NeuroOncology Conference

8 September 2012
17.15–18.45
Room CALLELONGUE
PARC CHANOT Convention & Exhibition Centre
Marseille, France

Faculty
Co-Chairs
Olivier Chinot, MD, PhD
University Hospital Timone
Marseille, France

Martin van den Bent, MD, PhD
Daniel den Hoed Cancer Center
Rotterdam, the Netherlands

Wolfgang Wick, MD, PhD
University of Heidelberg and German Cancer Research Center
Heidelberg, Germany

Michael Weller, MD
University Hospital of Zurich
Zurich, Switzerland

Target Audience
This educational activity is intended specifically for medical oncologists, neurologists, surgeons, and other healthcare professionals involved and/or interested in the management of patients with glioblastoma.

Educational Objectives
Upon completion of this educational activity, participants should be able to:

• Review current standards of care and goals of therapy for newly diagnosed glioblastoma
• Identify the rationale and mechanisms of action for emerging therapies for newly diagnosed glioblastoma
• Compare and contrast the safety and efficacy of novel therapeutic approaches for the treatment of newly diagnosed glioblastoma and the potential for integration of these therapies into current treatment paradigms

Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

www.prIMEoncology.org/glioblastoma2012
MSD Oncology is proud to support...

The 10th annual European Association of NeuroOncology (EANO) Congress 2012